A recent study has demonstrated that effective tumor necrosis factor-α-related apoptosis-inducing ligand (TRAIL)-based combination therapy can be achieved by upregulating DR4 and DR5 expression, and directly targeting tumor cell mitochondria to stimulate their apoptosis-inducing properties [21]. The gene discussed is TNFRSF10B; the disease is neoplasm.